TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24709256

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily for 12 weeks with PegIFN/RBV
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily for 24 weeks with PegIFN/RBV
Number of subjects: 160

Group type: COMPARATOR
Intervention: Both groups (12-week and 24-week) received identical treatment from weeks 2 to 12
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 22200674

Group type: EXPERIMENTAL
Intervention: DHA emulsion (docosahexaenoic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OA emulsion (oleic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Treatment (NT)
Number of subjects: 0
Study: 20409497

Group type: EXPERIMENTAL
Intervention: Web-based counseling (n=401)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Proactive telephone-based counseling (PTC; n=402)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Combined PTC and web counseling (n=399)
Number of subjects: 1202
Study: 17913317

Group type: EXPERIMENTAL
Intervention: Propofol 0.5mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol 0.5mg/kg plus dexamethasone 8 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 15914508

Group type: EXPERIMENTAL
Intervention: Low protein diet (0.8 g/kg; LP)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Moderate protein diet (1.8 g/kg; MP)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High protein diet (3.6 g/kg; HP)
Number of subjects: 5
Study: 11718736

Group type: EXPERIMENTAL
Intervention: PC-Fixator
Number of subjects: 1229
Study: 10229559

Group type: EXPERIMENTAL
Intervention: Iloprost i.v. infusion up to 2 ng/Kg/min for 6/h/day for 28 days (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Iloprost i.v. infusion up to 1.5 ng/Kg/min for 16/h/day for 7 days (Group B)
Number of subjects: 20
Study: 7913730

Group type: EXPERIMENTAL
Intervention: 500 mg of zidovudine daily
Number of subjects: 1565

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: 1500 mg of zidovudine daily
Number of subjects: 1565
Study: 2493733

Group type: EXPERIMENTAL
Intervention: Intravenous flecainide (2 mg/kg/10 minutes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Verapamil (10 mg/1 minute)
Number of subjects: 40
Study: 31651843

Group type: EXPERIMENTAL
Intervention: Yoga therapy (YT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 160
Study: 28692485

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5-3 mg/day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cariprazine 4.5-6 mg/day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cariprazine 9-12 mg/day
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 25289715

Group type: COMPARATOR
Intervention: Creatine (Cr; 5 g creatine plus 5 g maltodextrose)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Beta-alanine plus creatine (β‐ALA+Cr; 1.6 g beta alanine plus 5 g creatine plus 3.4 g maltodextrose)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Beta-alanine (β‐ALA; 1.6 g beta alanine plus 8.4 g maltodextrose)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (P; 10 g maltodextrose)
Number of subjects: 44
Study: 24239154

Group type: EXPERIMENTAL
Intervention: Short-term humanistic-existential psychotherapy (STP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard cardiological therapy only
Number of subjects: 101
Study: 21508145

Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Selenomethionine
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Levothyroxine plus selenomethionine
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 18827035

Group type: EXPERIMENTAL
Intervention: Cigarette packs with progressively fewer branding design elements
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Cardboard brown packs with minimal branding
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Plain packs
Number of subjects: 813

Group type: COMPARATOR
Intervention: Original branded packs
Number of subjects: 813
Study: 16014759

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 18

Group type: COMPARATOR
Intervention: None (non-supplemented)
Number of subjects: 18
Study: 12838090

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Sham manipulation
Number of subjects: 91

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 91
Study: 11129744

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 9053827

Group type: EXPERIMENTAL
Intervention: Calcium-enriched group (1200 mg RDA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (728 mg calcium)
Number of subjects: 22
Study: 1645047

Group type: EXPERIMENTAL
Intervention: Drug A (original piroxicam)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Drug B (generic piroxicam)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Drug C (another generic piroxicam)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic analysis
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chronic disease treatment
Number of subjects: 14
Study: 6389520

Group type: EXPERIMENTAL
Intervention: Lithium therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 84
Study: 29705152

Group type: EXPERIMENTAL
Intervention: 18FDG PET/CT
Number of subjects: 72

Group type: COMPARATOR
Intervention: 64MDCT
Number of subjects: 72
Study: 27323902

Group type: EXPERIMENTAL
Intervention: 2 cycles carboplatin-olaparib followed by olaparib monotherapy 300 mg BID
Number of subjects: 110

Group type: COMPARATOR
Intervention: Capecitabine 1250 mg/m2 BID day 1-14 q day 22
Number of subjects: 110
Study: 23870160

Group type: EXPERIMENTAL
Intervention: 2-dose methylprednisolone (30 mg/kg per dose, given 8 hours preoperatively and operatively)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Single-dose methylprednisolone (30 mg/kg per dose, given operatively)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups (2-dose and single-dose)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Postoperative response
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 2-dose methylprednisolone
Number of subjects: 68

Group type: COMPARATOR
Intervention: Single-dose methylprednisolone
Number of subjects: 68
Study: 23446065

Group type: EXPERIMENTAL
Intervention: Combination therapy (CBT + milnacipran 100 mg/d)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Milnacipran + education
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo + CBT
Number of subjects: 58
Study: 21097770

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Arginine-supplemented diets
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Supplemental parenteral glutamine
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: General RCTs
Number of subjects: 207
Study: 18426835

Group type: EXPERIMENTAL
Intervention: Elevated serum parathyroid hormone (PTH) levels (> or =63 ng/l, IV quartile cut point)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Elevated serum parathyroid hormone (PTH) levels after controlling for age, gender, co-morbidity, and creatinine
Number of subjects: 567

Group type: COMPARATOR
Intervention: Serum calcium (Ca(2+)) levels
Number of subjects: 567
Study: 15995109

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 1223
Study: 12926103

Group type: EXPERIMENTAL
Intervention: YM511 0.3 mg/day
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: YM511 (all doses)
Number of subjects: 98
Study: 10591935

Group type: EXPERIMENTAL
Intervention: Cervical spine motion analysis using three-dimensional electrogoniometry
Number of subjects: 289
Study: 9103689

Group type: EXPERIMENTAL
Intervention: HIV seropositive mothers
Number of subjects: 265

Group type: COMPARATOR
Intervention: HIV seronegative mothers
Number of subjects: 265
Study: 1909052

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 138

Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 138
Study: 6643335

Group type: EXPERIMENTAL
Intervention: Cefoperazone 2 g intravenous infusion over 15 min
Number of subjects: 10
Study: 3970361

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the periaqueductal gray region (n = 16)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No electrical stimulation (Control group, n = 17)
Number of subjects: 33
Study: 29038234

Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg subcutaneous every 4 weeks for 16 weeks (DB)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 16 weeks (DB)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Lanreotide during DB and IOL treatment
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo during DB and IOL treatment
Number of subjects: 115
Study: 27371758

Group type: EXPERIMENTAL
Intervention: n‐BiPAP
Number of subjects: 540

Group type: COMPARATOR
Intervention: n‐CPAP
Number of subjects: 540
Study: 24142804

Group type: EXPERIMENTAL
Intervention: Molsidomine (Coruno® 16 mg, once daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22865782

Group type: EXPERIMENTAL
Intervention: Exemestane (EXE) treatment
Number of subjects: 1485
Study: 19793779

Group type: EXPERIMENTAL
Intervention: Transbond‐LR
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fuji Ortho‐LC
Number of subjects: 40
Study: 18487894

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (3-month, 36 sessions)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 14
Study: 15680143

Group type: EXPERIMENTAL
Intervention: Assertions of permission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assertions of prohibitions
Number of subjects: 0
Study: 12573372

Group type: EXPERIMENTAL
Intervention: Intrahepatic arterial (IHA) chemotherapy (folinic acid 200 mg/m2, fluorouracil 400 mg/m2 over 15 mins and 22‐h infusion 1600 mg/m2, day 1 and 2, repeated every 14 days)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Intravenous chemotherapy (folinic acid 200 mg/m2, fluorouracil bolus 400 mg/m2 and 22‐h infusion 600 mg/m2, day 1 and 2, repeated every 14 days)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Both groups (IHA and intravenous)
Number of subjects: 290
Study: 10386280

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Droperidol 20 micrograms/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg plus Droperidol 20 micrograms/kg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Granisetron‐Droperidol combination
Number of subjects: 150
Study: 8681664

Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 1004

Group type: COMPARATOR
Intervention: pMDI
Number of subjects: 1004
Study: 1920171

Group type: EXPERIMENTAL
Intervention: Treatment of heart failure
Number of subjects: 0
Study: 6314107

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice a day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 29947060

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla300)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin degludec (Deg)
Number of subjects: 30
Study: 26902064

Group type: EXPERIMENTAL
Intervention: Video demonstration
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 80
Study: 23141150

Group type: EXPERIMENTAL
Intervention: M9L10 (melphalan 9 mg/m²/d and lenalidomide 10 mg/d)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: M6L10 (melphalan 6 mg/m²/d and lenalidomide 10 mg/d)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: M4L15 (melphalan 4 mg/m²/d and lenalidomide 15 mg/d)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: M5L10 (melphalan 5 mg/m²/d and lenalidomide 10 mg/d)
Number of subjects: 56
Study: 21600053

Group type: EXPERIMENTAL
Intervention: Peer mentorship program for 2 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 0
Study: 20128336

Group type: EXPERIMENTAL
Intervention: Strength Training (ST; n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (C; n = 12)
Number of subjects: 24
Study: 16466606

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg and 40 mg
Number of subjects: 151
Study: 15364675

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 11316351

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise training (40% VO2max) three times per week for 12 weeks in UB group
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise training (40% VO2max) three times per week for 12 weeks in LB group
Number of subjects: 21
Study: 9042047

Group type: EXPERIMENTAL
Intervention: Cinalukast 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cinalukast 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cinalukast 200 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7874603

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (42 micrograms/nostril) administered three times a day for 8 weeks
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo administered three times a day for 8 weeks
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 3280267

Group type: EXPERIMENTAL
Intervention: Anterior drainage through the abdominal wall
Number of subjects: 50

Group type: COMPARATOR
Intervention: Posterior drainage through the buttocks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Contamination of the sacral space due to rectum disrupture
Number of subjects: 50
Study: 31738173

Group type: EXPERIMENTAL
Intervention: Thrive intervention (n=181)
Number of subjects: 343
Study: 28424359

Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol 2.5/5 µg
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol 5/5 µg
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study: 25451471

Group type: EXPERIMENTAL
Intervention: Real Pharyngeal Electrical Stimulation (PES) - 0.2‐ms pulses, 5 Hz, 280 V, stimulation intensity at 75% of maximum tolerated threshold
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham Pharyngeal Electrical Stimulation (PES)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Real Pharyngeal Electrical Stimulation (PES)
Number of subjects: 14
Study: 24149180

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cediranib (20 mg)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 582
Study: 21080347

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional orthopedic care
Number of subjects: 86
Study: 20180668

Group type: EXPERIMENTAL
Intervention: Osmotic-release methylphenidate combined with cognitive-behavioral therapy
Number of subjects: 303

Group type: COMPARATOR
Intervention: Existing treatment program sources (treatment program staff, social services, juvenile justice system, mental health clinics)
Number of subjects: 303
Study: 16876497

Group type: EXPERIMENTAL
Intervention: Autologous serum
Number of subjects: 23

Group type: COMPARATOR
Intervention: Hyaluronic acid (Vislube)
Number of subjects: 23
Study: 12635391

Group type: COMPARATOR
Intervention: Gastric continuous enteral nutrition
Number of subjects: 43

Group type: COMPARATOR
Intervention: Gastric intermittent enteral nutrition
Number of subjects: 43

Group type: COMPARATOR
Intervention: Jejunal enteral nutrition
Number of subjects: 43
Study: 10711608

Group type: EXPERIMENTAL
Intervention: Extraction of the deciduous molar and mucogingival surgery (test site)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Extraction of the deciduous molar (control site)
Number of subjects: 8
Study: 9085107

Group type: EXPERIMENTAL
Intervention: Ketanserin 0.5% eye drops
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7871046

Group type: EXPERIMENTAL
Intervention: 0.28 g/kg alcohol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.36 g/kg alcohol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.54 g/kg alcohol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.72 g/kg alcohol
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.00 g/kg (placebo)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Higher alcohol doses
Number of subjects: 10
Study: 3486625

Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 14
Study: 30159938

Group type: EXPERIMENTAL
Intervention: Therapist adherence
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Years of clinical experience
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Competence
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Competence among therapists with formal CBT training
Number of subjects: 182
Study: 27061779

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg) administered at 01:00, 03:00, 05:00, and 07:00 on both nights (total of 800 mg/night)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo gum administered at 01:00, 03:00, 05:00, and 07:00 on both nights
Number of subjects: 24
Study: 25499937

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg self-administered via single 1 mL prefilled pen every 2 weeks (increased to 150 mg every 2 weeks at week 12 depending on LDL-C level)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/day
Number of subjects: 314

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day (statin rechallenge)
Number of subjects: 314
Study: 22930768

Group type: EXPERIMENTAL
Intervention: Tapered OSSEOTITE NT implants
Number of subjects: 20

Group type: COMPARATOR
Intervention: Straight-walled OSSEOTITE implants
Number of subjects: 20
Study: 21098467

Group type: EXPERIMENTAL
Intervention: European ancestry
Number of subjects: 4339
Study: 18176291

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (low-CHO)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 95
Study: 15623809

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 12519877

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (T)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10506405

Group type: EXPERIMENTAL
Intervention: Ty21a enteric-coated capsules (3 doses, every other day schedule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ty21a liquid formulation (3 doses, every other day schedule)
Number of subjects: 0
Study: 8777997

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg orally)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8273531

Group type: EXPERIMENTAL
Intervention: Hypnotic doses of propofol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam premedication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam (Valium)
Number of subjects: 0
Study: 2446752

Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m2 at 3-week intervals)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2 at 3-week intervals) and Tamoxifen (10 mg twice per day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Doxorubicin and Tamoxifen
Number of subjects: 59
Study: 29394449

Group type: EXPERIMENTAL
Intervention: Rapeseed oil (RO) diet
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Sunflower oil (SO) diet
Number of subjects: 111
Study: 26917606

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 μg twice daily
Number of subjects: 751

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751
Study: 25691681

Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide 1.0-3.0 g/day (2-6 tablets/day)
Number of subjects: 644

Group type: COMPARATOR
Intervention: Sevelamer 2.4-14.4 g/day (3-18 tablets/day)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide
Number of subjects: 644

Group type: COMPARATOR
Intervention: Sevelamer
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 644
Study: 24142086

Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Minimal intervention (control group)
Number of subjects: 637
Study: 20657177

Group type: EXPERIMENTAL
Intervention: DTPw‐HBVLT/Hib2.5 vaccine
Number of subjects: 192

Group type: COMPARATOR
Intervention: DTPw‐HBV/Hib10 vaccine
Number of subjects: 192
Study: 18258750

Group type: EXPERIMENTAL
Intervention: Taranabant (0.5-600 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Taranabant (0.5-600 mg) with high-fat meal
Number of subjects: 24
Study: 17063345

Group type: EXPERIMENTAL
Intervention: Sibutramine in combination with diet and lifestyle advice
Number of subjects: 8000

Group type: COMPARATOR
Intervention: Diet and lifestyle advice alone (control)
Number of subjects: 8000
Study: 12631097

Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10570622

Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg, 2 to 10 times daily) coadministered with levodopa/carbidopa or levodopa/benserazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Entacapone
Number of subjects: 0
Study: 7633695

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP) for 1 month
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no NCPAP)
Number of subjects: 35
Study: 2745343

Group type: EXPERIMENTAL
Intervention: 0.9% NaCl infusion (mean volume 1,280.3 +/- 107.3 ml)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No infusion (control)
Number of subjects: 9